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Rhus coriaria suppresses 
angiogenesis, metastasis and 
tumor growth of breast cancer 
through inhibition of STAT3, NFκB 
and nitric oxide pathways
Hussain El Hasasna1,*, Alaaeldin Saleh2,*, Halima Al Samri1, Khawlah Athamneh1, 
Samir Attoub3, Kholoud Arafat3, Nehla Benhalilou1, Sofyan Alyan1, Jean Viallet4, 
Yusra Al Dhaheri1, Ali Eid5,6 & Rabah Iratni1
Recently, we reported that Rhus coriaria exhibits anticancer activities by promoting cell cycle 
arrest and autophagic cell death of the metastatic triple negative MDA-MB-231 breast cancer cells. 
Here, we investigated the effect of Rhus coriaria on the migration, invasion, metastasis and tumor 
growth of TNBC cells. Our current study revealed that non-cytotoxic concentrations of Rhus coriaria 
significantly inhibited migration and invasion, blocked adhesion to fibronectin and downregulated 
MMP-9 and prostaglandin E2 (PgE2). Not only did Rhus coriaria decrease their adhesion to HUVECs 
and to lung microvascular endothelial (HMVEC-L) cells, but it also inhibited the transendothelial 
migration of MDA-MB-231 cells through TNF-α-activated HUVECs. Furthermore, we found that Rhus 
coriaria inhibited angiogenesis, reduced VEGF production in both MDA-MB-231 and HUVECs and 
downregulated the inflammatory cytokines TNF-α, IL-6 and IL-8. The underlying mechanism for Rhus 
coriaria effects appears to be through inhibiting NFκB, STAT3 and nitric oxide (NO) pathways. Most 
importantly, by using chick embryo tumor growth assay, we showed that Rhus coriaria suppressed 
tumor growth and metastasis in vivo. The results described in the present study identify Rhus coriaria 
as a promising chemopreventive and therapeutic candidate that modulate triple negative breast cancer 
growth and metastasis.
Breast cancer remains one of the most common cancers as well as one of the leading causes of worldwide 
cancer-related morbidity and mortality1. Conventional treatment for breast cancer includes radiation, surgery 
and chemotherapy. Despite the fact that these treatment modalities have improved over the last decade, prog-
nosis of this cancer remains poor. Common chemotherapeutic agents target three receptors: estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2)2. Breast cancer cells that 
lack ER, PR and show low HER2 levels are often referred to as triple negative breast cancer (TNBC)3. In addition 
to lacking the three receptors, most TNBC cells evade apoptosis and avoid DNA repair mechanisms4. Patients 
diagnosed with TNBC tend to have increased recurrence and mortality rate within 5 years of cancer detection 
and are thus considered to have poorer prognosis5,6. Even with combination treatment regimens, survival rates 
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of this highly metastatic type of cancer remain low. As such, novel compounds that could be more effective with 
potentially less side effects are critically needed.
Alternative approaches like herbal medicine have been sought and given more attention in recent years. 
Contextually, a large percent of women appear to be highly interested in using herbal remedies to prevent or treat 
breast cancer7. This increased interest is likely due to the fact that herbs and plants contain a bountiful presence 
of bioactive compounds such as: flavonoids, alkaloids and steroids in herbs and plants8. Indeed, most of the cur-
rently employed chemotherapeutic agents have been generated from or inspired by natural products. For exam-
ple, during the last three decades alone, only 20% of all new chemical entities introduced as drugs are classified as 
“synthetic”9. On the contrary, the majority of all cancer chemotherapeutic agents introduced since 1940 are either 
natural products, directly derived therefrom, or mimic one of these products9.
Among the different herbs included in the pharmacopeias of many countries especially in the Levant, the Rhus 
genus is known for its medicinal values10,11. This genus comprises more than 250 different species of flowering 
plants in the family Anacardiaceae10. Of particular interest is the species known as Rhus coriaria L., which is com-
monly known as sumac. Indeed, of all the Rhus species, Rhus coriaria is the most widely consumed species in the 
Mediterranean region12. Interestingly, the use of Rhus coriaria fruits in different countries on the rise13.
Rhus coriaria grows as a small tree with a height range of 1–4 meters in the wild14. The dried fruit of this plant 
is the most commonly consumed part and is typically used as a condiment, owing to its sour taste. Rhus coriaria 
has been shown to exhibit antimicrobial, anti-inflammatory, anti-fibrogenic, antifungal and anti-atherogenic 
properties10,11. Some of these capacities have been attributed to Rhus coriaria’s phenolic acids, flavonoids and tan-
nins11,15–17. We have recently shown that ethanolic extract of Rhus coriaria induces cell cycle arrest along with con-
comitant autophagic cell death of TNBCs18. However, whether it can modulate the metastatic phenotype of these 
cells remained largely obscure. Here, we sought to determine the effect of Rhus coriaria on the malignant behavior 
of MDA-MB-231 cells and determine the underlying mechanisms. Our results indicate that Rhus coriaria extract 
(RCE) abolishes the migration, invasion of TNBCs, suppresses angiogenesis and reduces tumor growth in vivo via 
inhibition of STAT3, NFκ B and nitric oxide (NO) pathways.
Materials and Methods
Cell culture and reagents. Human breast cancer cells MDA-MB-231(cat# 300275) were obtained from 
Cell line service (CLS)-GmbH. MDA-MB-231-GFP was previously described19. MDA-MB-231and MDA-MB-
231-GFP were maintained in DMEM (Hyclone, Cramlington, UK). All media were complemented with 10% fetal 
bovine serum (FBS) (Hyclone, Cramlington, UK), 100 U/ml penicillin/streptomycin (Hyclone, Cramlington, UK). 
Human Umbilical Vein Endothelial Cells (HUVECs) (Cat # C-003-5C) were obtained from (Life Technologies, 
Invitrogen). HUVECs were maintained in MEM 199 supplemented with 20% FBS, penicillin/streptomycin, 2 mM 
L-glutamine, 5 U/ml heparin and 50 μ g/ml endothelial cell growth supplements (BD Biosciences, Bedfrord, MA, 
USA). Human Lung Microvascular Endothelial Cells (HMVEC-L) (cat # CC-2527) were obtained from Lonza 
(Lonza, Walkersville, USA). HMVEC-L cells were maintained in EGM™ -2-MV BulletKit (Lonza, Walkersville, 
USA). Antibodies to NF-κ B, phospho-p65, TNF-α and iNOS were obtained from Abcam. Antibodies to STAT3, 
pSTAT3, β -actin, goat anti-mouse IgG-HRP (sc-2005) and goat anti-rabbit IgG-HRP (sc-2004) were obtained 
from Santa Cruz Biotechnology, Inc. LY294002 was purchased from Sigma-Aldrich.
Preparation of the Rhus coriaria Ethanolic Extract (RCE). Fruits of Rhus coriaria L. were collected 
from a private farm located at 33° 16′ 35.59″ N and 35° 19′ 02.89″ E. The farm is located in Ma’rakeh, Tyre, 
Lebanon and the approval of the owner was obtained before collecting the fruit or commencing any experiments. 
This plant is neither endangered nor protected by any laws and it is readily and commercially available in the 
market. RCE was prepared as previously described18. Briefly 10.0 g of the dried fruit were ground to a fine powder 
using a porcelain mortar and pestle. The powder was then suspended in 100 mL of 70% absolute ethanol and the 
mixture was kept in the dark for 72 hours at 4 °C in a refrigerator without stirring. After that, the mixture was 
then filtered through a glass sintered funnel and the filtrate was evaporated to dryness using a rota-vapor at room 
temperature. The red residue was kept under vacuum for 2–3 hours and its mass was recorded. The residue was 
stored at − 20 °C until further use.
Matrigel invasion assays. Invasiveness of the MDA-MB-231 cells treated with the RCE was tested using BD 
Matrigel Invasion Chamber (8-μ m pore size; BD Biosciences, Bedfrord, MA, USA) according to manufacturer’s 
instructions. Briefly, MDA-MB-231cells (1 × 105 /well) were placed in 0.5 mL of media containing vehicle (0.2% 
ethanol) or the indicated concentrations of RCE were seeded into the upper chambers of the system; the bottom 
wells in the system were filled with DMEM complemented with 10% fetal bovine serum as a chemo-attractant and 
then incubated at 37 °C for 24 h. Non-penetrating cells were removed from the upper surface of the filter with a 
cotton swab. Cells that have migrated though the matrigel were fixed with 4% formaldehyde, stained with DAPI. 
Fluorescence from DAPI was detected using a filter with excitation wavelength of 330–380 nm and barrier filter of 
400 nm. DAPI-stained nuclei were counted in 10 random fields per well using inverted fluorescence microscope 
at X200 magnification (Nikon Ti-U, Nikon). For quantification, the assay was done in duplicates and repeated 
three times.
Wound healing migration assay. Briefly, MDA-MB-231 cells were grown in six-well tissue culture dishes 
until confluency. A scrape was made through the confluent monolayer with a sterile plastic pipette tip. Three 
wounds were made for each sample. Afterwards, the plates were washed twice with PBS and incubated at 37 °C 
in fresh DMEM supplemented with 10% fetal bovine serum in the presence of vehicle (ethanol) or indicated 
concentrations of RCE. At the bottom side of each dish, three arbitrary places were marked where the width of 
the wound was photographed with an inverted microscope at X40 magnification (Nikon Ti-U, Nikon). Wound 
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closure was determined by measuring the distance (μ m) between the edges of the wound at time 0, 6 and 10 h, 
using the NIS-Elements BR 3.0 software (Nikon). Quantification of the distance migrated by the cells was done as 
follow: D = (Size of the wound at t = 0 h –size of the wound at t = 6 or 10 h).
Migration Chamber Assay. MDA-MB-231 cells (5 × 104/well) were seeded in the upper chamber of an 
insert system (BD Biosciences, USA) in serum-free medium, with or without RCE and migration assay was 
carried out according to the manufacturer’s instructions. Serum-containing medium was added to the lower 
chamber to act as a chemotactic attractant. After 6 hours of incubation, cells were washed with PBS, fixed with 
formaldehyde, and fixed with methanol. Cells were then stained with 1% crystal violet for 10 minutes. After wash-
ing with PBS, cells from at least five different random fields were counted under an inverted microscope.
Adhesion Assay. Adhesion of MDA-MB-231 to HUVECs or HMVEC-L was performed as previously 
described20,21. Briefly, MDA-MB-231 cells, transfected with Renilla luciferase, were loaded onto confluent mon-
olayers of endothelial cells in the presence of vehicle (0.2% ethanol) or RCE. Where indicated, TNF-α (25 ng/ml) 
was added for 6 hours to stimulate HUVECs prior to the addition of MDA-MB-231 cells. After 1 hour, unattached 
cells were removed by gently washing the plates three times with PBS. Adherent cells were lysed using a luciferase 
lysis buffer (Promega, Madison, WI, USA) and, luminescence was measured using Glomax 20/20 luminometer 
(Promega). The relative adhesion of MDA-MB-231 to endothelial cells (HUVECs or HMVEC-L) was expressed 
as the percentage of luminescence compared to the controls.
Adhesion to Fibronectin Assay. 96-well plates were coated with fibronectin (dissolved in PBS) and incu-
bated at 37 °C overnight. After that, plates were blocked with 3% Bovine Serum Albumin (BSA) for 3 hours at 
room temperature. MDA-MB-231 cells (5 × 103/well) were then seeded in growth medium and incubated for 
60 minutes in the humidified incubator (37 °C with 5% CO2). Cells were then washed 3 times with PBS to remove 
non-adherent cells. Attached cells were stained with crystal violet and observed under the microscope. At least 
five random fields were counted and the experiment repeated three times.
Transendothelial Migration Assay. Transendothelial migration of MDA-MB-231 through HUVECs was 
performed as previously described20,21. Briefly, transwell filters were coated with collagen and allowed to dry over-
night. HUVECs (2 × 105/well) were then seeded onto the rehydrated membrane and allowed to grow until a con-
fluent monolayer is formed. Where mentioned, TNF-α (25 ng/ml) was added for 6 hours to stimulate HUVECs. 
MDA-MB-231 cells (1 × 106/well) were then loaded on top and incubated overnight in the absence or presence of 
RCE. Cells on the upper chamber were removed with a cotton swab, whereas MDA-MB-231 on the bottom were 
stained and quantified as previously reported20.
Measurement of matrix metalloproteinases by ELISA. Cells were seeded in 6-well plates in the pres-
ence of vehicle (0.2% ethanol) or indicated concentrations of RCE for 24 hours. The conditioned medium was 
collected and the levels of secreted MMP-9 were determined using immunoassay kits (Abcam, Cambridge, UK) 
according to the manufacturer’s protocol. The optical density at 450 nm of each sample was measured using an 
AMP Platos R 496 microplate reader (AMP Diagnostics, Poland). The proteins present in the conditioned media 
were concentrated using the Amicon Ultra-15 protein purification and concentration column (Millipore) and 
protein concentration was assayed using the BCA protein assay kit (Thermo Scientific). Levels of MMP-9 were 
normalized to the total protein level in each sample. The assays were performed in triplicates and three independ-
ent experiments were performed. Data are presented as mean values ± SEM.
Vascular tube formation assay. Assessment of in vitro capillary formation used Matrigel (Becton 
Dickinson, Le Pont de Claix, France). Matrigel is a squamous cell carcinoma basement membrane matrix com-
posed primarily of collagen IV, laminin, entactin, and heparan sulfate proteoglycans. The Matrigel matrix was 
thawed, gently mixed to homogeneity using cooled pipettes, and diluted v/v with the EndoGRO™ -MV-VEGF 
Complete Media Kit medium (Millipore, Temecula, CA, USA). Matrigel, 50 μ l/well, supplemented with angi-
ogenic peptides and other effectors was used to coat the wells of 96-well plates. The plate was then incubated 
for one hour at 37 °C to allow the matrix solution to solidify prior to treatment. HUVECs (at a density of about 
4 × 104 cells/well) and the indicated concentration of RCE were plated to each well and incubated for 8 h at 37 °C 
in 0.1 mL of EndoGRO™ -MV-VEGF Complete Media Kit medium (Millipore, Temecula, CA, USA). Then, cells 
were photographed using an inverted phase contrast photomicroscope at X (40 × 1.6) magnification (Olympus 
1 × 71, Olympus). The tubular network growth area was compared in control and inhibitor-treated Matrigel 
matrix. Tube formation was quantified by counting the length of tube-like structures formed in each well. The 
effect of RCE on viability of the HUVECs was determined using a CellTiter-Glo Luminescent Cell Viability assay 
(Promega Corporation, Madison, USA), as previously described20. LY294002 (LY), an inhibitor of PI3K/AKT 
pathway and inhibitor of vascular tube formation, was used as positive controls for angiogenesis inhibition in 
this assay.
Transient transfection assay. MDA-MB-231 cells (1.5 × 105/well) were seeded in 12-well plates the day 
before transfection. Cells were then transfected with the pGL4.32[luc2P/NFκ B-RE/Hygro] expression plasmid 
(Promega, Madison, WI, USA) using Fugene HD (Promega, Madison, WI, USA) according to the manufactur-
er’s instructions. Briefly, 18 h post-transfection, cells were incubated for another 24 h in fresh complete media 
containing increasing concentrations of RCE. Luciferase activity was measured using Dual Luciferase Reporter 
Assay System (Promega, Madison, WI, USA). Renilla luciferase reporter was used as an internal control, to which 
firefly luciferase values were normalized. Experiments were repeated three times and the average of three means 
is represented ± SEM.
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Quantification of Nitrate/Nitrite production. The amount of Nitrate/Nitrite production was deter-
mined with a colorimetric ELISA kit (Cayman Chemical, Ann Arbor, Michigan, USA), which is based on the 
Griess reaction, according to the manufacturer’s instructions. The value of nitrate/nitrite presented is the total 
value measured in the presence of cells minus the value determined from the media alone in the absence of any 
growing cells. Assays were performed in triplicates and three independent experiments were performed. Data are 
presented as mean values ± SEM.
Quantitative Immunoassay for Human Vascular Endothelial Growth Factor (VEGF). Cells 
(1.5 × 105/well) were seeded in 24-well plates overnight in serum-containing culture media and then, the media 
was replaced by serum-free media. Cells were treated with vehicle (ethanol) or indicated concentrations of 
RCE and the conditioned media was collected at 24 h. The level of VEGF therein was measured using a VEGF 
enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN, USA) according to the manufactur-
er’s protocol. The optical density at 570 nm of each sample was measured using an AMP Platos R 496 microplate 
reader (AMP Diagnostics, Poland). The proteins present in the conditioned media were concentrated using the 
Amicon Ultra-0.5 protein purification and concentration column (Millipore) and protein concentration was 
assayed using the BCA protein assay kit (Thermo Scientific). Levels of VEGF were normalized to the total protein 
level in each sample. The assays were performed in triplicates and three independent experiments were per-
formed. Data are presented as mean values ± SEM.
ELISA quantification of cytokines. Cells (2 × 105/well) were cultured in a 6-well plate overnight and then 
serum-starved for 24 h in the presence of vehicle (ethanol) or indicated concentrations of RCE. Levels of IL-6, 
− 8, and − 11 in the collected media were measured using ELISA quantification kit (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s instructions. For PgE2, culture supernatants were assayed using an 
ELISA kit from Cayman Chemical (MI, USA). The optical density of each sample was measured using an AMP 
Platos R 496 microplate reader (AMP Diagnostics, Poland). The proteins present in the conditioned media were 
concentrated using the Amicon Ultra-0.5 protein purification and concentration column (Millipore) and protein 
concentration was assayed using the BCA protein assay kit (Thermo Scientific). Levels of the cytokines/PgE2 were 
normalized to the total protein level in each sample. Assays were performed in triplicates and three independent 
experiments were performed. Data are presented as mean values ± SEM.
Whole Cell extract and Western Blotting analysis. Cells (1.8 × 106) were seeded in 100 mm culture 
dishes and cultured for 24 h before addition of RCE at the indicated concentrations. After incubation, cells were 
washed twice with ice-cold PBS, scraped, pelleted and lysed in RIPA buffer (Pierce) supplemented with protease 
inhibitor cocktail (Roche) and phosphatase inhibitor (Roche). After incubation for 30 min on ice, cell lysates were 
centrifuged at 14,000 rpm for 20 min at 4 °C. Protein concentration of lysates was determined by BCA protein 
assay kit (Thermo Scientific) and the lysates were adjusted with lysis buffer. Aliquots of 25 μ g of total cell lysate 
were resolved onto 8–15% SDS-PAGE along with PageRuler Plus Prestained Protein Ladder (Thermo Scientific). 
Proteins were transferred to nitrocellulose membranes (Thermo Scientific) and blocked for 1 h at room tempera-
ture with 5% non-fat dry milk in TBST (TBS and 0.05% Tween 20). Incubation with specific primary antibodies 
was performed in blocking buffer overnight at 4 °C. Horseradish peroxidase-conjugated anti-IgG was used as sec-
ondary antibody. Immunoreactive bands were detected by ECL chemiluminescent substrate (Thermo Scientific). 
Where needed, membranes were stripped in Restore western blot stripping buffer (Thermo Scientific) according 
to the manufacturer’s instructions.
Animal Studies. All animal experiments were conducted in accordance with the French guidelines on 
the use of animals in scientific investigations with the approval of the local Ethical committee, (Institut Albert 
Bonniot, Grenoble, France: licence protocol N° 381029 and B3851610001).
Chick embryo tumor growth and metastasis assay. The chick embryo tumor growth assay 
(INOVOTION, Grenoble, France) was performed as previously described20,22. Briefly, Fertilized White Leghorn 
eggs, obtained from the Société Française de Production Agricole (SFPA, St. Brieuc, France), were incubated at 
38 °C with 60% relative humidity for 10 days. According to the French legislation, no ethical approval is needed 
for scientific experimentations using oviparous embryos (decree n° 2013–118, February 1, 2013; art. R-214–88). 
At stage E10, the chorioallantoic membrane (CAM) was dropped by drilling a small hole though the eggshell 
into the air sac and a 1 cm2 window was cut in the eggshell above the CAM. Cultured MDA-MB-231-GFP were 
detached by trypsinization, washed with complete medium and suspended in serum free DMEM. A 50 μ l inoc-
ulum of 1 × 106 MDA-MB-231-GFP cells was added onto the CAM of each egg. Eggs were then randomized in 4 
groups of 15 eggs (to get sufficient surviving embryos at the end of the experiments). One day later, tumors began 
to be detectable. They were then treated during 8 days, every two days (E11, E13, E15, E17), by dropping 100 μ l 
of either RCE (50 or 150 μ g/mL), colchicine (2 μ M) or vehicle (0.02% ethanol in PBS onto the tumor. At E19 the 
upper portion of the CAM was removed, transferred in PBS and the tumors were then carefully cut away from 
normal CAM tissue and weighted. In parallel, a 1 cm2 portion of the lower CAM was collected to evaluate the 
number of nodules, containing GFP-expressing cells. The fluorescent nodule were visualized in situ using whole 
mounts of tissue fixed in 4% formaldehyde in PBS and flattened between a hollow glass slide and a thick coverslip. 
In order to number the nodule, a thorough and complete visual scan of the piece of the lower CAM was done 
using Leica Macrofluo fluorescent microscope (Leica Microsystems GmbH) equipped with GFP filter. Chick 
embryos were sacrificed by decapitation.
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Statistical analysis. All statistical analysis were performed using SPSS version 21 for PC (IBM Corp.). Data 
were reported as group mean ± SEM. The data were analyzed via one-way ANOVA. Significance for all statistical 
comparisons was set at p < 0.05.
Results
Rhus coriaria attenuates the migration ability of MDA-MB-231 breast cancer cells. Because cell 
migration plays a crucial role in tumor metastasis, we first investigated the effect of RCE on the migration ability 
of MDA-MB-231 cells by using wound-healing migration assay. For this purpose, we performed the test with 
concentrations of RCE and periods of treatment that were non-cytotoxic to the MDA-MB-231 (Supplementary 
Figure 1). As shown in Fig. 1A and B, RCE treatment significantly inhibited cellular migration in a concentra-
tion-dependent manner. The ability of RCE to inhibit the migration of MDA-MB-231 cells was further con-
firmed using the Boyden chamber trans-well assay. As it is shown in Fig. 1C,D, the number of RCE (200 μ g/mL) 
-treated cells that has migrated to the lower chamber was markedly reduced by approximately three fold when 
compared to vehicle (ethanol)-treated cells. Taken together, our data demonstrate that RCE inhibits the migration 
potential of MDA-MB-231 cells.
Rhus coriaria inhibits the invasive potential of MDA-MB-231 cells, downregulates MMP-9 and 
prostaglandin E2, and reduces the adhesion of the breast cancer cells to fibronectin. Next, we 
examined the effect of RCE on the invasive potential of MDA-MB-231 cells in Matrigel-coated Boyden chamber 
in the presence of vehicle (ethanol) and RCE (10 and 50 μ g/mL). The number of RCE-treated cells that has passed 
through the Matrigel coated membrane was markedly reduced in concentration-dependent manner by 60 and 
Figure 1. Rhus coriaria inhibits the migration of MDA-MB-231 human breast cancer cells.  
(A) Confluent culture of MDA-MB-231 cells were wounded by scratching with a pipette tip and the cells were 
incubated in DMEM supplemented with 10% fetal bovine serum without and with indicated concentrations of 
RCE. The wound was measured with an inverted microscope x 40 magnification and photographed. (B) Wound 
healing assay showing that RCE inhibited the migration of MDA-MB-231 breast cancer cells in concentration-
dependent manner. Values represent the mean ± SEM (n = 3) distance (μ m) that the cells have migrated in 
6 and 10 h. Data are representative of three independent experiments. (C) Boyden chamber trans-well assay 
confirming that RCE inhibits the migration of MDA-MB-231 cells. Migrating MDA-MB-231 cells were stained 
with crystal violet and photographed with an inverted microscope at X100 magnification (Nikon Ti-U, Nikon). 
(D) Quantification of migrated MDA-MB-231 cells. The number of migrating MDA-MB-231 cells through 
Boyden chamber was quantified by counting at least 5 random fields at X200 magnification with an inverted 
microscope (Nikon Ti-U, Nikon). Data represent a mean ± SEM of cells counted per field and are representative 
of three independent experiments. Statistical analysis was performed using one-way ANOVA (*p < 0.05, 
**p < 0.005, ***p < 0.001).
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80%, respectively (Fig. 2A,B), indicating that RCE efficiently inhibits the invasive capability of MDA-MB-231 
cells.
Matrix metalloproteinase-9 (MMP-9), among other MMPs, is known to play an important role in breast can-
cer cell invasion and metastasis. To test whether Rhus coriaria inhibits breast cancer cell invasion by affecting 
the expression of MMP-9, we decided to examine the expression level of this protein in the conditioned medium 
using RCE-treated MDA-MB-231 cells. We found that secreted MMP-9 was significantly reduced in response to 
50 and 100 μ g/mL RCE treatment (Fig. 2C).
Prostaglandin E2 (PgE2) has been shown to be abundantly produced by various tumors, including breast can-
cer, and regulate cell growth, migration and invasion23,24. Here, we found that RCE could significantly reduce the 
level of PgE2 produced by the MDA-MB-231 breast cancer cells (Fig. 2D).
Cell movement and adhesion of tumor cells to components of the extracellular matrix (ECM), such as 
fibronectin, and to basement membrane represent a crucial event in the process of cancer invasion and metas-
tasis. Therefore, we also examined the effect of RCE on the ability of MDA-MB-231 to adhere to fibronec-
tin. Interestingly, we found that RCE was able to inhibit MDA-MB-231 cells adhesion to fibronectin in a 
concentration-dependent manner (Fig. 3A,B). This effect was robust and fast as it appeared within the first 60 min 
of contact, at time at which no cell death occurred (data not shown).
Altogether, these findings suggest that downregulation of MMP-9 and PgE2, and impaired ability of cells to 
adhere to component of the extracellular matrix in response to RCE, account at least partly, in the inhibition of 
invasion of MDA-MB-231 cells.
Rhus coriaria inhibits transendothelial migration of MDA-MB-231 through HUVECs and 
decreases their adhesion to HUVECs and to lung endothelial (HMVEC-L) cells. Migration of 
tumor cells through the vascular endothelium is a crucial event for metastasis, both during intravasation and 
extravasation. Here, we tested the ability of RCE-treated breast cancer cells to migrate through TNF-α stimulated 
HUVECs. As shown in Fig. 4A, transendothelial migration of RCE-treated MDA-MB-231 cells through the mon-
olayer of HUVECs was significantly attenuated by Rhus coriaria.
Because the attachment of tumor cells to endothelial blood vessels is an early event required for transendothe-
lial migration and hence for metastasis, we tested the effect of RCE on the ability of MDA-MB-231 cells to adhere 
to TNF-α stimulated HUVECs. As shown in Fig. 4B, RCE was able to inhibit, in a concentration-dependent 
manner, the adhesion of the cancer cells to HUVECs.
Figure 2. Rhus coriaria inhibits the invasion, downregulates MMP-9 and prostaglandin E2 (PgE2) .  
(A) MDA-MB-231 cells were incubated for 24 h with or without RCE (10 and 50 μ g/mL). Cells that invaded into 
the matrigel were scored as described in Materials and Methods. DAPI-stained nuclei of invading cells were 
photographed at X 100 magnification under an inverted microscope (Nikon Ti-U, Nikon). (B) Quantification of 
invaded MDA-MB-231 into the matrigel. Values represented in percent were calculated from three independent 
experiments and are represented as mean ± SEM. Statistical analysis was performed using one-way ANOVA 
(*p < 0.05, **p < 0.005, ***p < 0.001). (C,D) Effects of RCE on the secretion of MMP-9 (C) and PgE2 (D) in 
RCE-treated MDA-MB-231 cells. The levels of secreted MMP-9 and PgE2 were determined using immunoassay 
kits as described in Materials and Methods. Experiments were repeated three times in triplicate and the average 
of three means is represented ± SEM. Statistical analysis was performed using one-way ANOVA (*p < 0.05, 
**p < 0.005, ***p < 0.001).
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Figure 3. Rhus coriaria inhibits adhesion of MDA-MB-231 cells to fibronectin. (A) Effects of RCE on 
MDA-MB-231 cell adhesion to fibronectin-coated wells. MDA-MB-231 cells were seeded on the fibronectin-
coated wells with or without RCE. After 60 min of incubation, non-adhered cells were washed. Attached cells 
were stained with crystal violet and photographed with an inverted microscope at X100 magnification (Nikon 
Ti-U, Nikon). (B) Quantification of attached MDA-MB-231 cells to fibronectin. The number of adherent 
MDA-MB-231 cells to fibronectin was determined by counting at least 5 random fields per well at X200 
magnification with an inverted microscope (Nikon Ti-U, Nikon). Data represent a mean of cells counted per 
field and are representative of three independent experiments. Statistical analysis was performed using one-way 
ANOVA (***p < 0.001).
Figure 4. Rhus coriaria inhibits the migration of MDA-MB-231 cells across monolayer of TNF-α activated 
HUVECs and reduces their adhesion to HUVECs and lung endothelial cells (HMVEC-L). (A) Inhibition of 
transendothelial migration of MDA-MB-231 through TNF-α stimulated HUVECs. Confluent monolayers of 
HUVECs were pre-incubated with TNF-α (25 ng/mL) for 6 h, and transendothelial migration was evaluated 
after overnight incubation at 37 °C. Values represent means ± SEM, n = 3. Statistical analysis was performed 
using one-way ANOVA (*p < 0.05, **p < 0.005). (B,C) Inhibition of adhesion of MDA-MB-231 cells to 
HUVECs (B) and HMVEC-L (C). MDA-MB-231 cells were treated overnight with vehicle (0.2% ethanol) or 
indicated concentrations of RCE then seeded on top of the confluent endothelial cells and allowed to adhere for 
60 min as described in Materials and Methods. Adhesion of MDA-MB-231 cell was represented as percentage of 
cells that have adhered to HUVECs (B) or HMVEC-L (C). Data represent means ± SEM of three independent 
experiments. Statistical analysis was performed using one-way ANOVA (*p < 0.05, **p < 0.005).
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Lung is known to be a primary target for breast cancer metastasis. Therefore, we investigated the effect of 
RCE on the ability of MDA-MB-231 cells to attach to lung endothelial cells. Figure 4C shows that adhesion of 
MDA-MB-231 cells to pulmonary microvascular endothelial, HMVEC-L cells was also significantly inhibited by 
RCE, in a concentration-dependent manner (Fig. 4C).
Rhus coriaria inhibits angiogenesis and suppresses VEGF production in HUVECs and 
MDA-MB-231 cells. Tumor growth and metastasis critically depend on angiogenesis; therefore inhibiting 
this process would inhibit tumor expansion. We hence used HUVECs plated on Matrigel–coated plates to exam-
ine the effect of RCE on the formation of capillary tube in vitro. As shown in Fig. 5A,B, treatment of HUVECs 
with RCE significantly inhibited tube formation when compared with untreated cells. As expected, LY (20 μ M), 
used as positive controls for angiogenesis inhibition in this assay, also inhibited efficiently tube formation 
(Fig. 5B). RCE-mediated inhibition of tube formation occurred without reduction of cell viability of HUVECs, 
hence ruling out the possibility that the inhibition of tube formation is a consequence of cell death (Fig. 5C). Thus, 
our data demonstrates a potent anti-angiogenic activity of Rhus coriaria.
VEGF, a pro-angiogenic growth factor, plays an important role in angiogenesis. Therefore, we evaluated the 
effect of Rhus coriaria on the production of VEGF by MDA-MB-231 and HUVECs. Figure 6A shows that treat-
ment with increasing concentrations of RCE markedly reduced the secretion of VEGF by MDA-MB-231 cells. 
Subsequently, we measured the level of VEGF in MDA-MB-231 cells that were first treated with various con-
centrations of RCE and then stimulated with TNF-α . We found that the production of VEGF was enhanced in 
TNF-α -stimulated (1600 pg/mL) compared to vehicle (ethanol)-treated (800 pg/mL) MDA-MB-231 cells (Fig. 6B). 
However, VEGF production was significantly reduced by RCE in a concentration-dependent manner (Fig. 6B). 
We have also examined the VEGF production in TNF-α stimulated HUVECs. As expected, HUVEC cultured in 
the absence of TNF-α produced low level of VEGF (30 pg/mL), while in the presence of TNF-α stimulation, the 
production level rose to approximately 110 pg/mL (Fig. 6C). Importantly, exposure of HUVECs to RCE also led 
to a marked concentration-dependent suppression of VEGF production in these cells (Fig. 6C). Altogether, our 
results suggest that the inhibition of angiogenesis might be a consequence of downregulation of VEGF by RCE.
Rhus coriaria downregulates the expression of TNF-α protein and reduces levels of IL-6, and 
IL-8 production in breast cancer cells. Several studies reported that the cytokine TNF-α is involved 
in tumor cell motility and invasion of various cancer including TNBC. Hence, targeting TNF-α should be 
Figure 5. Effect of Rhus coriaria on the formation of capillary-like structures by HUVECs in vitro.  
(A) Patterns of angiogenesis induced by human umbilical vein endothelial cells (HUVECs) cultured on 
Matrigel matrix in 96-well plates with or without RCE. (B) Quantification of tubular morphogenesis induced 
in HUVECs cells cultured with or without RCE. Tube formation was determined by the length of tube-like 
structures containing connected cells. LY (20 μ M) was used as positive controls for angiogenesis inhibition in 
this assay. Data are mean ± S.E.M. from three independent experiments. Statistical analysis was performed using 
one-way ANOVA (*p < 0.05, **p < 0.005, ***p < 0.001). (C) Effect of RCE on cell viability of HUVECs. Viable 
cells were assayed as described in Materials and Methods. Columns represents mean; bars represents SEM.
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considered as a therapeutic approach for breast cancer treatment. Because we found that Rhus coriaria inhibited 
cell migration and invasion of MDA-MB-231, we sought to examine the effect of RCE on the expression of TNF-α 
by measuring the protein level of this cytokine. Figure 7A shows that RCE induced a marked reduction of TNF-α 
protein in MDA-MB-231 cells.
Next, we have examined the expression level of two other cytokines produced by breast cancers, namely IL-6 
and IL-8, which have been shown to increase growth and metastatic potential of breast cancer cells. Interestingly, 
we found that RCE also significantly reduced the level of both cytokines production in MDA-MB-231 cells in a 
concentration-dependent manner (Fig. 7B,C).
Hence, our data suggests that downregulation of TNF-α , IL-6 and IL-8 cytokines could account, at least partly, 
for the inhibition of tumor growth and metastasis mediated by Rhus coriaria.
Rhus coriaria attenuates STAT3 activation and inhibits NFκB pathway in MDA-MB-231 breast 
cancer cells. STAT3, activated by phosphorylation, is considered as mediator of tumorigenesis because of 
its role in promoting cellular proliferation, resistance to apoptosis, tumor angiogenesis, invasion, and migration 
of cancer cells25. Hence, STAT3 is widely recognized as a potential drug target for cancer therapy. To investigate 
whether Rhus coriaria affects the activation of STAT3 signaling in breast cancer cells, we analyzed the level of 
pSTAT3 in RCE-treated MDA-MB-231 cells. We found that RCE markedly reduced STAT3 phosphorylation, in 
concentration dependent-manner in MDA-MB-231 cells (Fig. 8A). This result suggests that the RCE-mediated 
effect on cell proliferation, migration and invasion in breast cancer involves the inhibition of STAT3 signaling in 
breast cancer cells.
The NFκ B signaling pathway is also known to regulate the expression of various genes involved in tumor cells 
invasion. To investigate whether RCE could affect this pathway, we first examined, by Western blotting, the phos-
phorylation status of phospho-p65 in RCE-treated MDA-MB-231 cells. We found that RCE drastically inhibited 
the phosphorylation of p65 (Fig. 8B). Next, we decided to measure the ability of RCE to inhibit NFκ B transcrip-
tional activity. Toward this, MDA-MB-231 cells were transiently transfected with an NFκ B reporter expression 
vector as described in materials and methods. As it is shown in Fig. 8C, RCE repressed NFκ B-dependent tran-
scription of the luciferase reporter in a concentration-dependent manner.
Taken together, our data clearly indicate that RCE exerts its effects on breast cancer cell proliferation, migra-
tion and invasion at least partly through an inhibition of two key signaling pathways, namely STAT3 and NFκ B, 
known to regulate several processes such as tumor growth and metastasis in breast cancer.
Figure 6. Reduced VEGF secretion in Rhus coriaria-treated HUVECs and MDA-MB-231 cells.  
(A) Quantification of basal level of VEGF secretion in conditioned medium from vehicle (0.2% ethanol) or 
RCE-treated MDA-MB-231 cells. MDA-MB-231 cells were treated with vehicle (ethanol) or the indicated 
concentrations of RCE for 24 h and then secreted VEGF, in the conditioned medium, was analyzed by ELISA 
as described in Materials and Methods. (B,C) Reduction of VEGF secretion in TNF-α induced MDA-MB-231 
cells (B) and HUVECs (C) cultured in presence of vehicle (ethanol) or indicated concentrations of RCE. VEGF 
secretion was quantified by ELISA as described above. Data represents means ± SEM of three independent 
experiments. Statistical analysis was performed using one-way ANOVA (*p < 0.05, **p < 0.005, ***p < 0.001).
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Reduced Nitric Oxide production in Rhus coriaria-treated MDA-MB-231 cells. Because nitric 
oxide (NO) signaling has also been shown to promote breast tumor growth and metastasis by altering the expres-
sion of genes implicated in cellular migration, invasion and angiogenesis26–28, we examined the effect of RCE on 
the NO production in MDA-MB-231 cells. Results in Fig. 8D clearly show that RCE decreased NO production in 
a concentration-dependent manner in MDA-MB-231 cells.
Inducible nitric oxide synthase (iNOS) is one of the three enzymes responsible for the NO synthesis and its 
overexpression is documented in breast cancer29–32. To further understand the mechanism of RCE inhibition of 
NO production, we examined the expression level of iNOS in RCE-treated MDA-MB-231 cells. Indeed, we found 
that treatment of these cells with RCE led to a decrease in the protein level of iNOS compared to untreated cells 
(Fig. 8E). Taken together, our results suggest that RCE could also exert its anti-metastatic effect by modulating the 
level of iNOS and consequently of NO production in breast cancer cells.
Rhus coriaria inhibits tumor growth and metastasis in chick embryo tumor growth and metas-
tasis assay. Finally, we tested the effect of Rhus coriaria on tumor growth in vivo by using the chick embryo 
model. MDA-MB-231 cells were grafted on the chorioallantoic membrane (CAM) and formed tumors were treated 
every 48 h with vehicle (ethanol), colchicine (2 μ M) or increased concentrations of RCE (50 and 150 μ g/mL). 
At E 19, tumors were recovered from the upper CAM and weighted. We found that RCE significantly inhibited 
tumor growth compared with the vehicle (ethanol) treatment even at low concentration. In fact, concentrations 
of only 50 μ g/mL RCE led to reduced tumor growth by 52% and a concentration of 150 μ g/mL led to a further 
reduction (63%) (Fig. 9A,B). We have also assessed for the ability of RCE to inhibit metastasis by counting the 
number of nodules in the lower CAM in vehicle (ethanol), colchicine- and RCE-treated tumors. An average of 
6.83 ± 1.85 nodules were counted in the lower CAM of vehicle (ethanol)-treated chick embryo, while an average 
of 3.33 ± 0.78 and 2.75 ± 0.87 nodules only were counted in 50 and 150 μ g/mL RCE-treated embryo (Fig. 9C), 
respectively. Altogether, our data clearly demonstrates that RCE could efficiently inhibit breast tumor growth and 
metastasis in vivo. Toxicity was also evaluated by comparing the number of dead embryos in control, colchicine- 
and RCE-treated embryos. At the end of the experiment ( E19), RCE showed no cytotoxicity as there was no 
difference in the number of surviving embryo in control and Rhus coriaria treatment (Fig. 9D).
Figure 7. Effects of Rhus coriaria on the expression of TNF-α, IL-6 and IL-8 cytokines in MDA-MB-231 
cells. (A) Western blot quantification of TNF-α protein in RCE-treated MDA-MB-231 cells. MDA-MB-231 
cells were treated with vehicle (0.2% ethanol) or indicated concentrations of RCE for 24 h, and then whole-cell 
extracts were subjected to Western blot analysis for TNF-α and β -actin proteins. Each lane was loaded with 
25 μ g of whole cell extracts. Loading was normalized to the levels of β -actin. The intensities of the bands were 
quantified using the ImageJ software (National Institute of Health, USA). (B,C) Reduction of IL-6 (B) and 
IL-8 (C) production in MDA-MB-231 cells. IL-6 and IL-8 production was quantified by ELISA as described in 
Materials and Methods. Data represents means ± SEM of three independent experiments. Statistical analysis 
was performed using one-way ANOVA (*p < 0.05, **p < 0.005).
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Discussion
Cancer metastasis requires several crucial interrelated events such as cancer cell adhesion, proteolytic degrada-
tion of and migration through the extra cellular matrix as well as angiogenesis. Current cancer treatment drugs 
aim at blocking cell cycle progression, inducing cell death and/or inhibiting tumor invasion and angiogenesis. 
Interestingly, cancer chemoprevention targeting these events has been reported for several natural compounds. 
Still, there is a growing interest in combination therapy using multiple anticancer drugs targeting several targets/
pathways. Our findings demonstrate for the first time that Rhus coriaria, at non-cytotoxic concentrations, exerts 
a potent anti-metastatic and anti-tumor growth activities against TNBC. Indeed, we report that Rhus coriaria 
inhibited the migration and invasion of MDA-MB-231 cells, blocked their adhesion to fibronectin, to HUVECs 
and to lung microvascular endothelial (HMVEC-L) and inhibited their transendothelial migration through 
TNF-α -activated HUVECs. Furthermore, we found that Rhus coriaria inhibited angiogenesis, reduced VEGF 
production in both MDA-MB-231 and HUVECs and downregulated MMP-9, PgE2, TNF-α , IL-6 and IL-8. 
Interestingly, our investigation revealed that NFκ B, STAT3 and Nitric Oxide (NO) pathways were inhibited in 
MDA-MB-231 in response to Rhus coriaria. Moreover, we demonstrated that Rhus coriaria significantly inhibited 
tumor growth and metastasis in vivo.
The ability of cancer cells to adhere to components of the extracellular matrix (ECM) is a pre-requisite 
process for cancer cell migration and thus represents one of the key steps in cancer metastasis. Indeed, it has 
Figure 8. Downregulation of STAT3, NFκB and iNOS and Reduction of Nitric Oxide (NO) production in Rhus 
coriaria-treated MDA-MB-231 cells. (A) Concentration-dependent decrease of phospho-STAT3 in RCE-treated 
MDA-MB-231 cells. MDA-MB-231 cells were treated with vehicle (0.2% ethanol) or indicated concentrations 
of RCE for 24 h, then whole-cell extracts were subjected to Western blot analysis for the phosphorylated and 
non-phosphorylated form of STAT3 and for β -actin (loading control). (B,C) Inhibition of the NFκ B signaling 
pathway by RCE. (B) Western blot analysis showing a concentration-dependent decrease of phospho-p65 (NFκ B) 
in MDA-MB-231 cells in response to RCE treatment. (C) Inhibition, by RCE, of NFκ B transcriptional activity in 
MDA-MB-231 cells. MDA-MB-231 cells were transfected with the pGL4.32[luc2P/NFκ B-RE/Hygro] expression 
plasmid and luciferase activity was measured 18 h post-transfection as described in Materials and Methods. 
Columns represents mean; bars represents SEM of three independent experiments. Statistical analysis was 
performed using one-way ANOVA (*p < 0.05, **p < 0.005, ***p < 0.001). (D–E) Reduction of Nitric Oxide (NO) 
production and downregulation of iNOS in RCE-treated MDA-MB-231 cells. (D) Quantification of NO levels in 
RCE-treated MDA-MB-231 cells. Cells were treated with vehicle (0.2% ethanol) or indicated concentrations of RCE 
for 24 h and Nitrate/Nitrite production was quantified as described in Materials and Methods. Statistical analysis was 
performed using one-way ANOVA (*p < 0.05, **p < 0.005, ***p < 0.001). Data represents means ± SEM of three 
independent experiments carried out in triplicate. (E) Western blot quantification of iNOS in cells treated without 
or with the indicated concentration of RCE. For western blot, each lane was loaded with 25 μ g of whole cell extracts. 
Loading was normalized to the levels of β -actin.The intensities of the bands were quantified using the ImageJ 
software (National Institute of Health, USA).
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been shown that the interaction of fibronectin, a component of the ECM, with specific cell surface receptors 
belonging to the integrin family, enhances the metastatic potential of breast cancer cells33. Hence, blocking the 
fibronectin-integrin would significantly diminish cell adhesion to ECM and consequently would block cell migra-
tion. Our data demonstrated that non-cytotoxic concentrations of Rhus coriaria markedly inhibited the adhesion 
of MDA-MB-231 to fibronectin as well as their migration. This inhibition may account, at least partly, for the 
anti-metastatic potential of Rhus coriaria on breast cancer cells. One may then hypothesize that Rhus coriaria 
might be a valuable source of potentially new compound(s) that can interfere with the adhesion of cancer cells 
to the ECM.
Dissemination of cancer cells from the primary tumor is another crucial event in the process of cancer inva-
sion and metastasis. This process involves degradation of the ECM through many proteases, of which MMP-9 
appears to play a key role34,35. Indeed, increased expression of MMPs correlates with increased growth, aggres-
siveness and metastatic potential of breast cancer cells36. Therefore, inhibiting these proteases is an important 
approach in the fight against breast cancer. Here, we clearly demonstrate that Rhus coriaria exerts its anti-invasive 
effects by decreasing MMP-9 levels and consequently reducing ECM degradation.
COX-2-derived prostaglandins are well known to promote proliferation, migration, invasion, and metastasis 
of cancer cells. One of the prostanoids that plays a vital role in malignancy is prostaglandin E2 (PgE2). A study by 
Singh and collaborators showed that COX-2 expression and the production of PgE2 in breast tumors stimulate 
bone metastasis in both mouse models and patients with breast cancer37. Downregulation of PgE2 production 
through inhibition of COX-2 in malignant breast cancer cells resulted in a significant attenuation of migration 
and invasion in MDA-MB-231 cells38. The development of agents that lower cellular levels of PgE2 might be 
very useful for treatment and prevention of breast cancer. Interestingly, we found that Rhus coriaria significantly 
reduced PgE2 production in MDA-MB-231 cells. Thus, our findings suggest that downregulation of PgE2 produc-
tion could be one of the mechanisms through which Rhus coriaria inhibits breast cancer tumorigenesis. As such, 
Rhus coriaria may turn out to be an important source for new inhibitors of COX-2/PgE2.
Figure 9. Anti-tumor growth and anti-metastatic activity of Rhus coriaria on breast tumor in chick embryo 
chorioallantoic membrane model system. (A) MDA-MB-231 (1 × 106) cells were grafted on the CAM of 10 
day (E10) chick embryo. Tumors were treated every 48 h with RCE as described in Materials and Methods. At 
E19, tumors were collected and weighted. (B) Quantification of tumor weight in vehicle (ethanol), colchicine 
and indicated concentrations of RCE-treated chick embryo. (C) Anti-metastatic effect of Rhus coriaria. 
Quantification of nodules observed in the lower CAM of chick embryo treated with vehicle (ethanol), colchicine 
or indicated concentrations of RCE. Columns represents mean; bars represents SEM. ***significantly different at 
p < 0.0005. (D) Toxicity screening of RCE on chick embryos. Toxicity was evaluated by comparing the number 
of dead embryos in control, colchicine- and RCE-treated embryos.
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Angiogenesis, a process by which new blood vessels form, is crucial for tumor growth and metastasis. 
Preventing this process would ultimately inhibit both tumor growth and metastasis39. Here, we showed that Rhus 
coriaria markedly blocked angiogenesis by inhibiting tube formation by HUVECs. One possible way to block 
angiogenesis is to target pro-angiogenic factors secreted by tumor cells such as VEGF. As matter of fact, VEGF 
is considered as a major pro-angiogenic protein expressed in 60% of breast cancer patients at the time of first 
diagnosis40. Importantly, we found that RCE significantly reduced the production of VEGF in both HUVECs 
and MDA-MB-231 cells and thus suggesting that one possible mechanism through which Rhus coriaria inhibits 
TNBC tumor growth is by blocking the process of angiogenesis.
Accumulating evidence suggests a strong association between inflammation and cancer progression41. 
Increased levels of inflammatory cytokines, such as IL-6, IL-8, and TNF-α , are known to promote migration, 
invasion and metastasis of various types of cancer including breast cancer42. Several studies identified IL-6, 
IL-8 and TNF-α as important factors of poor prognosis in TNBC, given their role in promoting invasion and 
metastasis43–45. Hence, inhibition of these signaling pathways offers a promising strategy in targeting TNBC. 
Recently, Hartman and collaborators reported that growth of TNBC relies upon coordinate autocrine expression 
of IL-6 and IL-8. Moreover, concurrent inhibition of these two cytokines inhibited colony formation in vitro and 
tumor growth in vivo of TNBC cells46. Similarly, inhibition of MDA-MB-231 tumor xenografts by ulinastatin 
and docetaxel was associated with downregulation of the expression of IL-6, IL-8 and TNF- α 47. It is also known 
that TNF-α increasesIL-6 production48. Interestingly, here we showed that RCE inhibited both TNF-α and IL-6 
production in MDA-MB-231 cells. It is then possible to postulate that RCE inhibition of IL-6 occurs by virtue of 
its ability to suppress the TNF signaling route. Moreover, we also showed that RCE could efficiently inhibit IL-8 
production. Taken together, our data strongly suggests that one possible mechanism through which RCE inhibits 
invasion and tumor growth involves inhibition of IL-6, IL-8 and TNF-α pathways.
Transcription factors including NFκ B and STAT3 play crucial roles in transmitting signals of inflammatory 
cytokines to the nucleus49. The NFκ B signaling pathway, which can be activated by TNF-α , is known to activate 
the expression of various genes involved in the process of tumor metastasis and growth and its inactivation sup-
press metastasis of breast cancer cells. Moreover, inactivation of NFκ B in breast cancer cells inhibits the expres-
sion of many target genes involved in tumor metastasis and tumor growth such as MMP-950, VEGF50, IL-646 and 
IL-846.
In the present work, we demonstrated that Rhus coriaria inhibited the NFκ B signaling through down-
regulation of phospho-p65 as well as its downstream targets (MMP-9, VEGF, IL-6 and IL-8), all of which are 
involved in tumor metastasis. It is noteworthy to mention that Rhus coriaria also efficiently inhibited TNF-α 
in MDA-MB-231 cells. It appears then that inhibition of NFκ B could account, although not solely, for the 
anti-metastatic effects of Rhus coriaria. We can hypothesize that one possible mechanism by which Rhus coriaria 
exerts its anti-metastatic and anti-tumor growth of TNBC involves the downregulation of TNF-α .
Constitutive activation of STAT3 was described in various types of cancers including breast cancer. The 
critical role of STAT3 in tumor cell survival, proliferation, tumor cell invasion, metastasis and angiogene-
sis is well-established and thus targeting STAT3 for therapy assaults cancer on multiple fronts51,52. A possible 
mechanism through which STAT3 is hyperactivated in tumors involves the autocrine production of IL-6 from 
tumor cells49. Indeed, in cancer inflammatory environment, IL-6 induces dimerization of IL-6 receptors, lead-
ing to activation of STAT353. This increased activation can then promote cancer progression and metastasis. 
Interestingly, in MDA-MB-231, STAT3 can itself increase the expression of IL-6 for further activation of STAT354. 
Interestingly, we found that Rhus coriaria inhibited STAT3 phosphorylation in a concentration-dependent man-
ner in MDA-MB-231 cells, thus suggesting that STAT3 inactivation might contribute to the anti-cancer effect of 
Rhus coriaria. Most importantly, IL-6 production was also reduced in response to Rhus coriaria. Thus, our data 
suggest that reduction of IL-6 production might contribute, at least partly, to the inhibition of STAT3 in TNBC.
Nitric Oxide (NO) is a signaling molecule that regulates several physiological processes such as vasodilatation, 
cell migration, immune reactions and apoptosis28. Interestingly, NO can also promote or inhibit tumor progres-
sion and metastasis. The pro- or anti-tumorigenic activities of NO have been related to the p53 status55,56. For 
example, NO-mediated apoptosis in leukemia cells requires wild-type p5357. On the other hand, carcinoma cells 
with mutant p53 and expressing iNOS/NOS2 have accelerated tumor growth and increased VEGF production30. 
Recent studies showed that increased iNOS/NOS2 and consequently NO production, predicted poor survival in 
patients with TNBC30. Moreover, exposure to NO enhanced cell motility and invasion of Estrogen Receptor neg-
ative cells30. Selective iNOS inhibitor (1400W) diminished cell proliferation and migration and inhibited tumor 
growth of TNBC cells58. It appears then that discovery of new inhibitors targeting NO production may be par-
ticularly efficacious against TNBC patients. Here, we showed that Rhus coriaria significantly downregulated iNOS 
and consequently decreased NO production in TNBC. Taken together, these data indicate that Rhus coriaria 
might also exert its anti-metastatic effect by targeting the NO signaling pathway.
In conclusion, our data clearly demonstrate that Rhus coriaria exerts a potent anti-angiogenic, anti-metastatic 
and anti-tumor growth effects on TNBC by targeting multiple key pathways employed by TNBC to acquire a 
rather aggressive phenotype. Our findings provide the first instance of a potential role for Rhus coriaria as an 
anti-breast cancer agent and certainly deserves more attention for further explorations to identify novel effective 
therapeutic compound(s) against TNBC.
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